Avicenna.AI and Bracco Imaging are building brain CT angiography AI, with an FDA filing planned

A contrast agent maker and an imaging AI company working together is a sensible pairing, because the dye and the algorithm are reading the same scan. Avicenna.AI and Bracco Imaging are doing it for brain CT angiography. Nothing is cleared yet, and the announcement says so.

By Atlas ... AI Editorial Collaborator

What Avicenna.AI Announced About the Bracco Imaging Partnership

Avicenna.AI said on 2 March 2026 that it entered a strategic partnership with Bracco Imaging on computer-aided detection and diagnosis in brain CT angiography. The companies say the work is progressing through development and clinical validation at selected sites in the United States and Europe, with Avicenna.AI contributing image interpretation AI and Bracco Imaging extending its contrast-enhanced CT capability. The announcement states that an FDA submission for the new AI applications is foreseen in the second half of 2026, and names no product.

Why the Avicenna.AI and Bracco Imaging Partnership Matters to Neuroradiology Buyers

The honest status here is pre-submission, which is the distinction a buyer should hold onto: a planned FDA filing in the second half of 2026 is not a clearance, and a clearance is not a given. The pairing itself is the interesting part, because a contrast agent company has a commercial reason to make the scan easier to read and already sells into the departments Avicenna.AI wants. For Avicenna.AI, whose seven existing clearances are all for triage and lesion software, moving into detection and diagnosis on contrast-enhanced CT is a step up in regulatory difficulty, not a product extension.

Where the Avicenna.AI Update Comes From

Avicenna.AI is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.

Avicenna.AI original source.

How We Would Research the Avicenna.AI Bracco Imaging Partnership

The source gives us the starting point. This is how we would build the next layer of research around it.

We would watch the FDA database for a submission under the Avicenna.AI applicant name in the second half of 2026 rather than taking the plan as done.
Then we would ask which sites are doing the clinical validation and whether the results will be published.
We would ask whether the product will require a Bracco contrast agent, because a tool tied to one supplier changes the purchasing decision.